Browse by topic
- View All
- Agricultural and Vet Science
- Arts, Culture and Performance
- Built Environment and Design
- Business and Management
- COVID-19 Related
- Digital Technology Supercluster
- Earth Sciences
- Environmental Sciences
- History and Archaeology
- Human Society
- Indigenous Studies
- Information and Computing Science
- International Development
- Language, Communications and Culture
- Law and Legal Studies
- Medical and Health Science
- Philosophy and Religious Studies
- Policy and Political Science
- Research Tools
Accelerating Drug Discovery for Frontotemporal Degeneration RFP
There are currently no FDA approved disease-modifying treatments available for frontotemporal dementia (FTD), and symptomatic treatments only provide limited benefit for patients. Recent scientific advances have provided an increased understanding of pathogenic mechanisms underlying FTD and are driving the development of potential disease-modifying therapies. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate this progress by supporting innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy etc.) drug development programs for FTD through this request for proposals (RFP).
The RFP supports:
- Lead optimization of novel disease-modifying compounds, including medicinal chemistry refinement and in vitro ADME.
- In vivo testing of novel lead compounds, biologics, vaccines, or repurposed drug candidates in relevant animal models for pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies.
This RFP does NOT support target identification, target validation, assay development, high-throughput and high-content screening. IND-enabling work is supported through ADDF’s Drug Development RFP.
The average duration of the award is one year with potential for follow-on funding, and the average award amount is $100,000-$200,000 based on stage and scope of research.
Funding is open to researchers and clinicians in the U.S. and worldwide working in:
- Academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
- Biotechnology companies that demonstrate a clear need for nonprofit funding. Existing companies and new spinouts are both eligible.
Submission of application
Applicants should submit a Letter of Intent (LOI) through the ADDF Funding Portal.
Letter of Intent: May 19th, 2023
Invited Full Proposal: July 28th, 2023
For more information please visit the Opportunity's Website
SFU Signature Sheet and Full Application are due to ORS three (3) business days before the application deadline.